文献速递眼底病与葡萄膜炎

光生物调节治疗干性年龄相关性黄斑变性的长期疗效与安全性:LIGHTSITE III 24个月分析

LONG-TERM EFFICACY AND SAFETY OF PHOTOBIOMODULATION IN DRY AGE-RELATED MACULAR DEGENERATION (LIGHTSITE III: 24-MONTH ANALYSIS).
PubMed 文献 · Retina · 2026-01-01

LIGHTSITE III为双盲随机假对照前瞻性研究,纳入148眼(100例)干性AMD,接受多波长PBM或假治疗24个月。21个月时PBM组BCVA较假组显著改善(P=0.0036),PBM组视力增益+6.2字母;24个月时地图样萎缩发生率显著降低(假组24.0% vs PBM组6.8%,P=0.007),安全性良好。

要点

  • PBM在21个月时BCVA较假组显著改善(P=0.0036),PBM组增益+6.2字母。
  • 24个月时地图样萎缩发生率假组24.0% vs PBM组6.8%(P=0.007)。
  • 未观察到光毒性等安全信号,视觉生活质量显著获益。

核心结论

  • 多波长PBM可恢复干性AMD患者视功能,并可能具有疾病修饰作用。

研究设计与样本

  • LIGHTSITE III为双盲、随机、假对照、平行组、前瞻性研究,纳入148眼(100例)干性AMD患者。
  • 治疗组接受多波长PBM(Valeda光递送系统;590、660、850 nm),每4个月一个疗程(3–5周内每周3次、共9次),持续24个月。

主要发现

  • 21个月时PBM组BCVA较假组显著改善(P=0.0036),PBM组增益+6.2字母。
  • 21个月时PBM治疗眼中61.5%增益≥5字母、23.1%增益≥10字母、4.4%增益≥15字母。
  • 24个月时地图样萎缩发生率假组24.0% vs PBM组6.8%(P=0.007)。
  • 视觉生活质量(QoL)显著获益,未观察到光毒性征象。

关键数值与推荐

  • 主要BCVA疗效终点在21个月达到,组间差异P=0.0036。
  • 24个月地图样萎缩发生率组间差异P=0.007。

临床怎么用

  • 多波长PBM可作为中间期干性AMD的干预选择,可能恢复视功能并降低地图样萎缩发生风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety and efficacy of multiwavelength photobiomodulation (PBM) in nonexudative (dry) age-related macular degeneration (AMD). METHODS: LIGHTSITE III used a double-masked, randomized, sham-controlled, parallel-group, prospective study design. Subjects were enrolled with a diagnosis of dry AMD and treated with multiwavelength PBM (Valeda Light Delivery System; 590, 660, and 850 nm) or sham treatment. A treatment series included 9 PBM or sham treatments delivered 3x/week over 3 to 5 weeks every 4 months (M) for 24M. RESULTS: A total of 148 eyes (100 subjects) with dry AMD were randomized into the study. LIGHTSITE III met the prespecified primary BCVA efficacy end point at M21 with a significant difference between treatment groups ( P = 0.0036) and a +6.2 letter gain after PBM. At M21, 61.5% of PBM-treated eyes showed ≥5, 23.1% showed ≥10, and 4.4% showed ≥15 letter gains. A favorable safety profile was observed with no signs of phototoxicity. Disease progression to Geographic Atrophy (GA) showed a significant decrease in incidence (Sham, 24.0% vs. PBM, 6.8%; P = 0.007) after PBM treatment at M24. Significant benefit in vision QoL was observed. CONCLUSION: Multiwavelength PBM represents an interventional therapy that restores visual function and has potential disease-modifying effects in intermediate dry AMD.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Jaffe GJ, Boyer D, Hu A, et al. LONG-TERM EFFICACY AND SAFETY OF PHOTOBIOMODULATION IN DRY AGE-RELATED MACULAR DEGENERATION (LIGHTSITE III: 24-MONTH ANALYSIS). Retina. 2026. PMID: 41791029. doi:10.1097/IAE.0000000000004822

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。